| Patents for C07K 16 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies (149,320) |
|---|
| 01/06/2011 | WO2011002525A1 Methods for treatment of muscular dystrophy |
| 01/06/2011 | WO2011001882A1 Flagellin mutant capable of effectively inducing protective capability on infection by pseudomonas aeruginosa |
| 01/06/2011 | WO2011001366A1 N-terminal truncated amyloid beta protofibrils/ oligomers for use in therapeutic and diagnostic methods for alzheimer's disease |
| 01/06/2011 | WO2011001029A1 Detection of igfbp-4 fragments as a diagnostic method |
| 01/06/2011 | WO2011000929A1 Neurotoxins exhibiting shortened biological activity |
| 01/06/2011 | WO2011000543A1 Murine antibody display library |
| 01/06/2011 | WO2011000054A1 Immuno-conjugates and methods for producing them |
| 01/06/2011 | WO2010131009A3 Treatment of il-25 mediated diseases with tlr antagonists |
| 01/06/2011 | WO2010124009A3 Fully human anti-vegf antibodies and methods of using |
| 01/06/2011 | WO2010119991A3 Anti-hgf antibody combinational cancer therapies |
| 01/06/2011 | WO2010115998A3 Improved amino acid sequences directed against il-6r and polypeptides comprising the same for the treatment of il-6r related diseases and disorders |
| 01/06/2011 | WO2010115555A3 Antibodies against human tweak and uses thereof |
| 01/06/2011 | WO2010112033A3 Method for estimating the risk of having or developing multiple sclerosis using sequence polymorphisms in a specific region of chromosome x |
| 01/06/2011 | WO2010111633A3 Antibody composition with altered fab sialylation |
| 01/06/2011 | WO2010104761A3 Anti-cd40 antibodies and uses thereof |
| 01/06/2011 | WO2010088691A3 Compositions and methods for treating or preventing conditions and diseases associated with mannheimia haemolytica |
| 01/06/2011 | WO2010060102A3 Prediction and prevention of preeclampsia |
| 01/06/2011 | US20110004952 Method for the separation of cells |
| 01/06/2011 | US20110004949 Immunoglobulin 1 |
| 01/06/2011 | US20110004948 Immunoglobulin 2 |
| 01/06/2011 | US20110003974 Modified fluorescent proteins and methods for using same |
| 01/06/2011 | US20110003973 Antibodies to zalpha11 cytokine receptors |
| 01/06/2011 | US20110003972 Stabilizing polypeptides which have been exposed to urea |
| 01/06/2011 | US20110003971 Modulators and modulation of the interaction between rgm and neogenin |
| 01/06/2011 | US20110003969 Conjugation methods |
| 01/06/2011 | US20110003734 Proteins and polynucleotides of vibrio cholerae |
| 01/06/2011 | US20110003711 Cell lines expressing gaba receptor and methods using them |
| 01/06/2011 | US20110003399 Tumor Necrosis Factor-Gamma |
| 01/06/2011 | US20110003383 Antibodies to ht5gj57 |
| 01/06/2011 | US20110003362 Conjugates of biological substances |
| 01/06/2011 | US20110003339 Pathogenic Escherichia Coli Associated Protein |
| 01/06/2011 | US20110003337 Immunoglobulin compositions and methods of producing same |
| 01/06/2011 | US20110003336 Methods for Increasing the Therapeutic Efficacy of Immunoglobulin G Class 3 (IgG3) Antibodies |
| 01/06/2011 | US20110003335 Methods for prognosing the status of tumor patients |
| 01/06/2011 | US20110003319 Transgenic Trasnchromosomal Rodents for Making Human Antibodies |
| 01/06/2011 | US20110003318 Nucleotide and protein sequence of mammastatin and methods of use |
| 01/06/2011 | US20110003314 Hapten, Immunogens and Derivatives of Ascomycin Useful for Preparation of Antibodies and Immunoassays |
| 01/06/2011 | US20110003313 Amplified labeled conjugate for use in immunoassays |
| 01/06/2011 | US20110003278 H5 Subtype-Specific Binding Proteins Useful for H5 Avian Influenza Diagnosis and Surveillance |
| 01/06/2011 | US20110002957 Hapten-carrier conjugates for treating and preventing nicotine addiction |
| 01/06/2011 | US20110002945 Use of immunoglobulin heavy and light chains or fragments thereof to bind to aggregated amyloidogenic proteins |
| 01/06/2011 | US20110002943 Use of enterovirus for diagnostics, treatment and prevention of disease |
| 01/06/2011 | US20110002942 Engineered Anti-IL-23 Antibodies |
| 01/06/2011 | US20110002941 Antibodies that Specifically Bind Hedgehog-Derived Polypeptides |
| 01/06/2011 | US20110002939 monoclonal antibody and a method thereof |
| 01/06/2011 | US20110002937 Method of making hybrid cells that express useful antibodies |
| 01/06/2011 | US20110002936 Anti-IL-6/IL-6R Antibodies and Methods of Use Thereof |
| 01/06/2011 | US20110002935 Antibody purification |
| 01/06/2011 | US20110002933 Dr4 antibodies and uses thereof |
| 01/06/2011 | US20110002932 POLY-N-ACETYL GLUCOSAMINE (PNAG/dPNAG)-BINDING PEPTIDES AND METHODS OF USE THEREOF |
| 01/06/2011 | US20110002931 Bispecific antibodies that bind to complement proteins |
| 01/06/2011 | US20110002929 Amino acid sequences directed against rank-l and polypeptides comprising the same for the treatment of bone diseases and disorders |
| 01/06/2011 | US20110002927 Antigen-binding polypeptides against cartilage degeneration |
| 01/06/2011 | US20110002926 Hepatitis c virus antibodies |
| 01/06/2011 | US20110002924 Tweak receptor agonists as anti-angiogenic agents |
| 01/06/2011 | US20110002922 Cell growth inhibitors containing anti-glypican 3 antibody |
| 01/06/2011 | US20110002919 Antagonists of neuropilin receptor function and use thereof |
| 01/06/2011 | US20110002917 Antibody constant domain regions and uses thereof |
| 01/06/2011 | US20110002916 Plasmodium falciparum antigens and their vaccine and diagnostic applications |
| 01/06/2011 | US20110002913 Use of interleukin-4 antagonists and compositions thereof |
| 01/06/2011 | US20110002910 Therapeutic agents comprising pro-apoptotic proteins |
| 01/06/2011 | US20110002887 Combinations of antibodies selective for dr5 and other therapeutic agents |
| 01/06/2011 | CA2767063A1 Novel therapeutic and diagnostic means |
| 01/06/2011 | CA2766899A1 Compositions and methods for diagnosing and/or treating influenza infection |
| 01/06/2011 | CA2766794A1 Markers of xmrv infection and uses thereof |
| 01/06/2011 | CA2766770A1 Novel antibodies and their uses in therapeutic and diagnostic methods |
| 01/06/2011 | CA2766641A1 Polypeptides and method of treatment |
| 01/06/2011 | CA2766409A1 Immuno-conjugates and methods for producing them |
| 01/06/2011 | CA2765602A1 N-terminal truncated amyloid beta protofibrils/ oligomers for use in therapeutic and diagnostic methods for alzheimer's disease |
| 01/06/2011 | CA2763692A1 Neurotoxins exhibiting shortened biological activity |
| 01/05/2011 | EP2270509A1 Method for detection of liver cancer cell using anti-glypican-3 antibody |
| 01/05/2011 | EP2270504A2 Techniques for growth and differentiation of human pluripotent stem cells |
| 01/05/2011 | EP2270209A2 Identification of surface-associated Antigenes used for the diagnosis and therapy of tumours |
| 01/05/2011 | EP2270177A1 Streptococcus pneumoniae proteins and nucleic acids |
| 01/05/2011 | EP2270176A1 Streptococcus pneumoniae proteins and nucleic acids |
| 01/05/2011 | EP2270175A1 Streptococcus pneumoniae proteins and nucleic acids |
| 01/05/2011 | EP2270169A2 Neisseria meningitidis antigenic polypeptides, corresponding polynucleotides and protective antibodies |
| 01/05/2011 | EP2270158A2 Bitter taste receptors |
| 01/05/2011 | EP2270157A2 Bitter taste receptors |
| 01/05/2011 | EP2270156A2 Bitter taste receptors |
| 01/05/2011 | EP2270155A2 Bitter taste receptors |
| 01/05/2011 | EP2270154A2 Bitter taste receptors |
| 01/05/2011 | EP2270153A2 Bitter taste receptors |
| 01/05/2011 | EP2270150A2 Method for controlling the activity of immunologically functional molecule |
| 01/05/2011 | EP2270149A2 Method for controlling the activity of immunologically functional molecule |
| 01/05/2011 | EP2270148A2 Method for controlling the activity of immunologically functional molecule |
| 01/05/2011 | EP2270147A2 Method for controlling the activity of immunologically functional molecule |
| 01/05/2011 | EP2270144A1 Partial peptide of survivin presented on mhc class ii molecule and use thereof |
| 01/05/2011 | EP2270054A2 Anti-idiotype antibodies of the human monoclonal antibody SC-1, and their production and use |
| 01/05/2011 | EP2270053A1 Humanized AXL antibodies |
| 01/05/2011 | EP2270052A2 Antibodies to OPGL |
| 01/05/2011 | EP2270051A2 Antibody specific for human PD-1 and CD3 |
| 01/05/2011 | EP2270050A1 Anti-CD19 antibodies with reduced immunogenicity |
| 01/05/2011 | EP2270049A2 Recombinant anti-interleukin-9-antibody |
| 01/05/2011 | EP2270048A2 Anti-NGF antibodies and methods using same |
| 01/05/2011 | EP2270047A2 Anti-C5 antibodies and their therapeutic uses |
| 01/05/2011 | EP2270046A2 Methods and compositions for the treatment of hemolysis-associated diseases |
| 01/05/2011 | EP2270045A1 Antibodies against Clostridium difficile toxins and uses thereof |
| 01/05/2011 | EP2270044A1 Liquid immunoglobulin G (lgG) product |
| 01/05/2011 | EP2270027A1 Polypeptides having brain-localizing activity and uses thereof |